{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:30:32Z","timestamp":1758040232283,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.amjcard.2020.08.002","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T20:39:41Z","timestamp":1596832781000},"page":"149-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-684X","authenticated-orcid":false,"given":"Dimitrios","family":"Patoulias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Katsimardou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Styliani","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.08.002_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0003","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0004","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.amjcard.2016.06.016","article-title":"Usefulness of left ventricular mass and geometry for determining 10-year prediction of cardiovascular disease in adults aged >65 years (from the Cardiovascular Health Study)","volume":"118","author":"Desai","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0005","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2008.09.014","article-title":"The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study","volume":"52","author":"Bluemke","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1148\/radiol.2019182871","article-title":"Left ventricular mass at MRI and long-term risk of cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"293","author":"Kawel-Boehm","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0007","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0008","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","article-title":"Chapter 9: Analyzing data and undertaking meta-analyses","author":"Deeks","year":"2011"},{"year":"2014","series-title":"Review Manager (RevMan) [Computer program] Version [5.3]","key":"10.1016\/j.amjcard.2020.08.002_bib0009"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0010","first-page":"29","article-title":"A revised tool for assessing risk of bias in randomized trials","volume":"10","author":"Higgins","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0011","doi-asserted-by":"crossref","first-page":"1356\u20101359","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0012","doi-asserted-by":"crossref","first-page":"1693\u20101702","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0013","first-page":"ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial [published online ahead of print, 2020 Jun 24]","author":"Brown","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0014","doi-asserted-by":"crossref","first-page":"44\u201052","DOI":"10.2337\/db15-0627","article-title":"Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes","volume":"65","author":"Levelt","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2020.08.002_bib0015","doi-asserted-by":"crossref","first-page":"15348","DOI":"10.1038\/s41598-019-51949-5","article-title":"Effect of empagliflozin on cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes mellitus","volume":"9","author":"Hsu","year":"2019","journal-title":"Sci Rep"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920308213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920308213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:35:12Z","timestamp":1757572512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920308213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":15,"alternative-id":["S0002914920308213"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.08.002","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}